Presseportal.de - Pieris AGhttp://www.presseportal.de/pm/61954/pieris-ag/rssPresseportal.de: Pieris AG (Digitale Pressemappe)de-denews aktuell GmbHhttp://www.presseportal.de/images/logo_napresseportal.gifPresseportal.de - Pieris AGhttp://www.presseportal.de/pm/61954/pieris-ag/rssredaktion@presseportal.de (Jens Petersen)Sat, 11 Feb 2012 02:44:24 +0100Tue, 07 Feb 2012 11:00:08 +01006Pieris Receives BMBF Grant to Fund PRS-110 c-Met Antagonist Anticalin® Program / Grant Supports Personalized Anti-cancer Approach on Path to ClinicPieris AG: Freising, Germany (ots) - Pieris AG announced today the receipt of a EUR 1 million grant to support the development of the company's proprietary PRS-110 compound targeting c-Met, a cellular receptor that plays a key role in cancer cell growth and ...http://www.presseportal.de/pm/61954/2194140/pieris-receives-bmbf-grant-to-fund-prs-110-c-met-antagonist-anticalin-program-grant-supports/rssTue, 07 Feb 2012 11:00:08 +0100http://www.presseportal.de/pm/61954/2194140/pieris-receives-bmbf-grant-to-fund-prs-110-c-met-antagonist-anticalin-program-grant-supports/rss Pieris AG [Pressemappe]
Freising, Germany (ots) - Pieris AG announced today the receipt of a EUR 1 million grant to support the development of the company's proprietary PRS-110 compound targeting c-Met, a cellular receptor that plays a key role in cancer cell growth and ... Lesen Sie hier weiter...
]]>Wirtschaftredaktion@presseportal.de (Jens Petersen)Excelitas TechnologiesPieris Presents Preclinical Data for PRS-080 Hepcidin Antagonist Anticalin® Program at ASH Annual MeetingPieris AG: San Diego, CA, USA (ots) - Breadth of Pharmacokinetic Data Points to Tunable Half-life for Platform Pieris AG presented novel preclinical in vitro and in vivo data for its PRS-080 Anticalin hepcidin antagonist in an oral presentation at the ...http://www.presseportal.de/pm/61954/2164791/pieris-presents-preclinical-data-for-prs-080-hepcidin-antagonist-anticalin-program-at-ash-annual/rssTue, 13 Dec 2011 11:00:14 +0100http://www.presseportal.de/pm/61954/2164791/pieris-presents-preclinical-data-for-prs-080-hepcidin-antagonist-anticalin-program-at-ash-annual/rss Pieris AG [Pressemappe]
San Diego, CA, USA (ots) - Breadth of Pharmacokinetic Data Points to Tunable Half-life for Platform Pieris AG presented novel preclinical in vitro and in vivo data for its PRS-080 Anticalin hepcidin antagonist in an oral presentation at the ... Lesen Sie hier weiter...
]]>Wirtschaftredaktion@presseportal.de (Jens Petersen)Excelitas TechnologiesPieris Announces Results and Successful Completion of its PRS-050 Anticalin Phase I Trial at AACR-EORTC-NCI Molecular Targets and Cancer Therapeutics ConferencePieris AG: San Francisco, California (ots) - --Results Establish Safety, Tolerability, Lack of Immunogenicity and PK/PD Profile for First Anticalin in a Clinical Setting-- Pieris AG presented the results of the Company?s first clinical evaluation of ...http://www.presseportal.de/pm/61954/2148096/pieris-announces-results-and-successful-completion-of-its-prs-050-anticalin-phase-i-trial-at-aacr/rssTue, 15 Nov 2011 11:37:20 +0100http://www.presseportal.de/pm/61954/2148096/pieris-announces-results-and-successful-completion-of-its-prs-050-anticalin-phase-i-trial-at-aacr/rss Pieris AG [Pressemappe]
San Francisco, California (ots) - --Results Establish Safety, Tolerability, Lack of Immunogenicity and PK/PD Profile for First Anticalin in a Clinical Setting-- Pieris AG presented the results of the Company?s first clinical evaluation of ... Lesen Sie hier weiter...
]]>Wirtschaftredaktion@presseportal.de (Jens Petersen)Excelitas TechnologiesPieris Outlines Strategic Impact of Six Million Euro EUROCALIN Grant Award on Anticalin(R) Pipeline DevelopmentPieris AG: Freising (ots) - In concert with the award of the EU FP7 Grant to the Pieris-led EUROCALIN Consortium that will enable initial clinical development of Pieris' proprietary hepcidin antagonist program, the company announced today the positive ...http://www.presseportal.de/pm/61954/2132301/pieris-outlines-strategic-impact-of-six-million-euro-eurocalin-grant-award-on-anticalin-r-pipeline/rssWed, 19 Oct 2011 11:01:00 +0200http://www.presseportal.de/pm/61954/2132301/pieris-outlines-strategic-impact-of-six-million-euro-eurocalin-grant-award-on-anticalin-r-pipeline/rss Pieris AG [Pressemappe]
Freising (ots) - In concert with the award of the EU FP7 Grant to the Pieris-led EUROCALIN Consortium that will enable initial clinical development of Pieris' proprietary hepcidin antagonist program, the company announced today the positive ... Lesen Sie hier weiter...
]]>Wirtschaftredaktion@presseportal.de (Jens Petersen)Excelitas TechnologiesEUROCALIN Consortium Initiates EU Grant Funded Collaboration to Develop Novel Anticalin Therapeutic to Treat AnemiaPieris AG: Freising, Germany (ots) - - Consortium Will Receive Six Million Euro from Seventh Framework Programme The EUROCALIN Consortium, comprising 10 companies and universities from across Europe, has initiated a collaboration focused on attaining ...http://www.presseportal.de/pm/61954/2132296/eurocalin-consortium-initiates-eu-grant-funded-collaboration-to-develop-novel-anticalin-therapeutic/rssWed, 19 Oct 2011 11:00:18 +0200http://www.presseportal.de/pm/61954/2132296/eurocalin-consortium-initiates-eu-grant-funded-collaboration-to-develop-novel-anticalin-therapeutic/rss Pieris AG [Pressemappe]
Freising, Germany (ots) - - Consortium Will Receive Six Million Euro from Seventh Framework Programme The EUROCALIN Consortium, comprising 10 companies and universities from across Europe, has initiated a collaboration focused on attaining ... Lesen Sie hier weiter...
]]>Wirtschaftredaktion@presseportal.de (Jens Petersen)Excelitas TechnologiesPieris Announces Preclinical In Vitro and In Vivo Data for its Anticalin(R) PRS-080 Hepcidin Antagonist Drug Program / Data to be presented at BioIron Society Meeting in VancouverPieris AG: Freising (ots) - Pieris AG announced today preclinical in vitro and in vivo data for its PRS-080 Anticalin antagonist program targeting hepcidin, a small peptide which plays a pivotal role in the regulation of iron levels in the blood. PRS-080 ...http://www.presseportal.de/pm/61954/2049449/pieris-announces-preclinical-in-vitro-and-in-vivo-data-for-its-anticalin-r-prs-080-hepcidin/rssMon, 23 May 2011 11:00:04 +0200http://www.presseportal.de/pm/61954/2049449/pieris-announces-preclinical-in-vitro-and-in-vivo-data-for-its-anticalin-r-prs-080-hepcidin/rss Pieris AG [Pressemappe]
Freising (ots) - Pieris AG announced today preclinical in vitro and in vivo data for its PRS-080 Anticalin antagonist program targeting hepcidin, a small peptide which plays a pivotal role in the regulation of iron levels in the blood. PRS-080 ... Lesen Sie hier weiter...
]]>Wirtschaftredaktion@presseportal.de (Jens Petersen)Excelitas TechnologiesPieris and Daiichi Sankyo Sign Therapeutic Collaboration to Develop Anticalin(R) TherapeuticsPieris AG: Freising, Germany (ots) - Pieris AG announced today the signature of a collaboration and license agreement with Daiichi Sankyo Company Limited (hereinafter Daiichi Sankyo; headquartered in Chuo Ward, Tokyo, TSE 4568), under which Pieris will apply ...http://www.presseportal.de/pm/61954/2025161/pieris-and-daiichi-sankyo-sign-therapeutic-collaboration-to-develop-anticalin-r-therapeutics/rssTue, 12 Apr 2011 11:00:00 +0200http://www.presseportal.de/pm/61954/2025161/pieris-and-daiichi-sankyo-sign-therapeutic-collaboration-to-develop-anticalin-r-therapeutics/rss Pieris AG [Pressemappe]
Freising, Germany (ots) - Pieris AG announced today the signature of a collaboration and license agreement with Daiichi Sankyo Company Limited (hereinafter Daiichi Sankyo; headquartered in Chuo Ward, Tokyo, TSE 4568), under which Pieris will apply ... Lesen Sie hier weiter...
]]>Wirtschaftredaktion@presseportal.de (Jens Petersen)Excelitas TechnologiesPieris to Present at BioCentury Future Leaders in the Biotech Industry ConferencePieris AG: Freising (ots) - Pieris AG announced today that Stephen Yoder, Chief Executive Officer, is scheduled to present at the 18th Annual BioCentury Future Leaders in the Biotech Industry Conference 2011, to be held Friday, April 15, 2011 at the Millennium ...http://www.presseportal.de/pm/61954/2024240/pieris-to-present-at-biocentury-future-leaders-in-the-biotech-industry-conference/rssMon, 11 Apr 2011 11:00:00 +0200http://www.presseportal.de/pm/61954/2024240/pieris-to-present-at-biocentury-future-leaders-in-the-biotech-industry-conference/rss Pieris AG [Pressemappe]
Freising (ots) - Pieris AG announced today that Stephen Yoder, Chief Executive Officer, is scheduled to present at the 18th Annual BioCentury Future Leaders in the Biotech Industry Conference 2011, to be held Friday, April 15, 2011 at the Millennium ... Lesen Sie hier weiter...
]]>Wirtschaftredaktion@presseportal.de (Jens Petersen)Excelitas TechnologiesPieris to Present Interim Data from the Phase I Clinical Trial of PRS-050 at Molecular Medicine Tri-ConferencePieris AG: Freising, Germany (ots) - Pieris AG announced today the upcoming presentation of new preclinical and interim Phase I clinical trial data for its PRS-050 Anticalin( program, currently under evaluation for the treatment of cancer. Dr. Laurent Audoly, ...http://www.presseportal.de/pm/61954/1770196/pieris-to-present-interim-data-from-the-phase-i-clinical-trial-of-prs-050-at-molecular-medicine-tri/rssTue, 22 Feb 2011 10:00:34 +0100http://www.presseportal.de/pm/61954/1770196/pieris-to-present-interim-data-from-the-phase-i-clinical-trial-of-prs-050-at-molecular-medicine-tri/rss Pieris AG [Pressemappe]
Freising, Germany (ots) - Pieris AG announced today the upcoming presentation of new preclinical and interim Phase I clinical trial data for its PRS-050 Anticalin( program, currently under evaluation for the treatment of cancer. Dr. Laurent Audoly, ... Lesen Sie hier weiter...
]]>Wirtschaftredaktion@presseportal.de (Jens Petersen)Excelitas TechnologiesTakeda San Francisco and Pieris Sign Anticalin® Therapeutic CollaborationPieris AG: San Francisco, USA and Freising, Germany (ots) - Takeda San Francisco (TSF) and Pieris AG have signed a drug discovery partnership agreement under which Pieris will apply its Anticalin® scaffold technology to deliver protein therapeutic candidates ...http://www.presseportal.de/pm/61954/1745625/takeda-san-francisco-and-pieris-sign-anticalin-therapeutic-collaboration/rssMon, 10 Jan 2011 11:00:00 +0100http://www.presseportal.de/pm/61954/1745625/takeda-san-francisco-and-pieris-sign-anticalin-therapeutic-collaboration/rss Pieris AG [Pressemappe]
San Francisco, USA and Freising, Germany (ots) - Takeda San Francisco (TSF) and Pieris AG have signed a drug discovery partnership agreement under which Pieris will apply its Anticalin® scaffold technology to deliver protein therapeutic candidates ... Lesen Sie hier weiter...
]]>Wirtschaftredaktion@presseportal.de (Jens Petersen)Excelitas TechnologiesPieris Signs Broad Collaboration with Sanofi-Aventis and Sanofi Pasteur to Develop Anticalin TherapeuticsPieris AG: Freising-Weihenstephan (ots) - Pieris AG announced today the signature of a collaboration and license agreement with both Sanofi-Aventis and Sanofi Pasteur, the vaccines division of the sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), under which ...http://www.presseportal.de/pm/61954/1689646/pieris-signs-broad-collaboration-with-sanofi-aventis-and-sanofi-pasteur-to-develop-anticalin/rssTue, 28 Sep 2010 12:15:56 +0200http://www.presseportal.de/pm/61954/1689646/pieris-signs-broad-collaboration-with-sanofi-aventis-and-sanofi-pasteur-to-develop-anticalin/rss Pieris AG [Pressemappe]
Freising-Weihenstephan (ots) - Pieris AG announced today the signature of a collaboration and license agreement with both Sanofi-Aventis and Sanofi Pasteur, the vaccines division of the sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), under which ... Lesen Sie hier weiter...
]]>Wirtschaftredaktion@presseportal.de (Jens Petersen)Excelitas TechnologiesPieris Initiates Phase I Clinical Trial for Lead Anticalin Compound / Anti-VEGF PRS-050 is first Anticalin tested in humansPieris AG: Freising-Weihenstephan (ots) - Pieris AG announced today the initiation of a Phase I clinical trial in cancer patients for its lead program, PRS-050, an anti-VEGF Anticalin. The trial is an open-label, dose-escalating evaluation of the compound's ...http://www.presseportal.de/pm/61954/1631561/pieris-initiates-phase-i-clinical-trial-for-lead-anticalin-compound-anti-vegf-prs-050-is-first/rssTue, 15 Jun 2010 10:55:15 +0200http://www.presseportal.de/pm/61954/1631561/pieris-initiates-phase-i-clinical-trial-for-lead-anticalin-compound-anti-vegf-prs-050-is-first/rss Pieris AG [Pressemappe]
Freising-Weihenstephan (ots) - Pieris AG announced today the initiation of a Phase I clinical trial in cancer patients for its lead program, PRS-050, an anti-VEGF Anticalin. The trial is an open-label, dose-escalating evaluation of the compound's ... Lesen Sie hier weiter...
]]>Wirtschaftredaktion@presseportal.de (Jens Petersen)Excelitas TechnologiesPieris AG Appoints Chief Scientific OfficerPieris AG: Freising-Weihenstephan (ots) - Pieris AG announced today that Laurent Audoly, Ph.D., has joined the company as Chief Scientific Officer, effective immediately. Dr. Audoly, most recently Biologics Research Site Lead at Merck & Co. Inc., brings both ...http://www.presseportal.de/pm/61954/1626439/pieris-ag-appoints-chief-scientific-officer/rssMon, 07 Jun 2010 10:17:02 +0200http://www.presseportal.de/pm/61954/1626439/pieris-ag-appoints-chief-scientific-officer/rss Pieris AG [Pressemappe]
Freising-Weihenstephan (ots) - Pieris AG announced today that Laurent Audoly, Ph.D., has joined the company as Chief Scientific Officer, effective immediately. Dr. Audoly, most recently Biologics Research Site Lead at Merck & Co. Inc., brings both ... Lesen Sie hier weiter...
]]>Wirtschaftredaktion@presseportal.de (Jens Petersen)Excelitas TechnologiesPieris Announces Positive Preclinical Data on c-Met Anticalin Drug ProgramPieris AG: Freising-Weihenstephan (ots) - Novel Approach with PRS-110 Shows Dose-dependent Response in Cancer Model Pieris AG announced today preclinical data for its proprietary PRS-110 Anticalin" compound, which targets the c-Met receptor, demonstrating a ...http://www.presseportal.de/pm/61954/1605249/pieris-announces-positive-preclinical-data-on-c-met-anticalin-drug-program/rssFri, 30 Apr 2010 10:27:55 +0200http://www.presseportal.de/pm/61954/1605249/pieris-announces-positive-preclinical-data-on-c-met-anticalin-drug-program/rss Pieris AG [Pressemappe]
Freising-Weihenstephan (ots) - Novel Approach with PRS-110 Shows Dose-dependent Response in Cancer Model Pieris AG announced today preclinical data for its proprietary PRS-110 Anticalin" compound, which targets the c-Met receptor, demonstrating a ... Lesen Sie hier weiter...
]]>Wirtschaftredaktion@presseportal.de (Jens Petersen)Excelitas TechnologiesPieris Appoints a New CEO / Appointment will bring substantial deal-making expertise to the companyPieris AG: Freising-Weihenstephan, Germany (ots) - Pieris AG today announced the appointment of Stephen S. Yoder as CEO with immediate effect. Mr. Yoder takes over the position from interim CEO and co-founder Claus Schalper, who will remain CFO. Mr. Yoder ...http://www.presseportal.de/pm/61954/1538868/pieris-appoints-a-new-ceo-appointment-will-bring-substantial-deal-making-expertise-to-the-company/rssMon, 04 Jan 2010 10:00:05 +0100http://www.presseportal.de/pm/61954/1538868/pieris-appoints-a-new-ceo-appointment-will-bring-substantial-deal-making-expertise-to-the-company/rss Pieris AG [Pressemappe]
Freising-Weihenstephan, Germany (ots) - Pieris AG today announced the appointment of Stephen S. Yoder as CEO with immediate effect. Mr. Yoder takes over the position from interim CEO and co-founder Claus Schalper, who will remain CFO. Mr. Yoder ... Lesen Sie hier weiter...
]]>Wirtschaftredaktion@presseportal.de (Jens Petersen)Excelitas Technologies